- Everolimus enhances 5-FU efficacy in HER2-negative breast cancer.
- Everolimus downregulates thymidylate synthase (TYMS) by inducing proteasomal degradation via reduced O-GlcNAcylation.
- Overexpression of O-GlcNAc transferase (OGT) reverses TYMS degradation.
- Combination strategy effective in refractory breast cancer patients.
- Decreased TYMS and OGT levels observed post-everolimus treatment in patients.